Fulcrum Therapeutics (FULC) Common Equity: 2019-2025
Historic Common Equity for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $198.4 million.
- Fulcrum Therapeutics' Common Equity fell 22.90% to $198.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.4 million, marking a year-over-year decrease of 22.90%. This contributed to the annual value of $243.0 million for FY2024, which is 3.33% up from last year.
- Per Fulcrum Therapeutics' latest filing, its Common Equity stood at $198.4 million for Q3 2025, which was down 7.47% from $214.4 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Common Equity ranged from a high of $296.3 million in Q1 2023 and a low of $110.9 million during Q2 2021.
- Over the past 3 years, Fulcrum Therapeutics' median Common Equity value was $243.0 million (recorded in 2024), while the average stood at $244.7 million.
- In the last 5 years, Fulcrum Therapeutics' Common Equity spiked by 122.25% in 2021 and then fell by 27.90% in 2024.
- Over the past 5 years, Fulcrum Therapeutics' Common Equity (Quarterly) stood at $211.5 million in 2021, then declined by 5.95% to $198.9 million in 2022, then climbed by 18.22% to $235.2 million in 2023, then climbed by 3.33% to $243.0 million in 2024, then dropped by 22.90% to $198.4 million in 2025.
- Its last three reported values are $198.4 million in Q3 2025, $214.4 million for Q2 2025, and $228.5 million during Q1 2025.